Clinical trial
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in…
NCT00063141 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00063141 |
|---|---|
| Title | Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer |
| Official title | Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | cetuximab, Irinotecan |
| Enrollment | 1,302 |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Jun 25, 2003 |
| Last update posted | Apr 12, 2010 |
| Countries | Australia, Austria, Belgium, Czechia, Finland, France, Germany, Hong Kong, Italy, Netherlands, Norway, Portugal and 5 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: